Medical Device Marketing: Where Commercial Leaders Are Reallocating Budget

The story inside medical device commercial leadership right now is not that budgets are growing. It is that budgets are moving. Investment is shifting away from rep-heavy field models and broad conference spend toward hybrid coverage, AI-enabled commercial operations, and digital programs that reach buying committees where they actually research. The companies running this reallocation well are outpacing the ones still running the playbook that defined the industry a decade ago.

This piece looks at where medical device marketing budgets are shifting, which categories of spend are quietly underperforming, and what the strongest reallocations have in common. It draws on the EY Pulse of the MedTech Industry Report, McKinsey's research on hybrid medtech sales and commercial capabilities, PwC's industry outlook, and Veeva Pulse benchmark data on HCP engagement.

Key Takeaways

• Top-line growth is stable, but reallocation is accelerating. EY's industry data shows medical device revenue growth holding steady at 6 to 7 percent, with commercial leaders putting that growth into restructuring how they invest rather than expanding spend.
• Rep-only models are being reshaped, not replaced. Field coverage stays, but it is increasingly paired with remote-sales teams and AI-augmented account support.
• Digital is now the dominant HCP channel for many medtech buyers. Veeva's Pulse data shows companies running inbound digital programs see digital share of HCP engagement climb from 22 to 58 percent.
• High-growth therapeutic categories warrant disproportionate investment. PwC's analysis names pulse field ablation, structural heart, robotics, and diabetes as categories where reallocation toward growth pays off; mature businesses are sustained leaner.
• The underperforming spend categories are predictable. Generic conference activation, untargeted programmatic display, and rep coverage in mature categories without digital augmentation are the most common stalls.

What's Driving the Reallocation

The macro picture is stable enough to give commercial leaders room to make structural changes. According to the EY Pulse of the MedTech Industry Report, the global medical technology industry has now recorded seven consecutive years of top-line growth, reaching $584 billion. Commercial leaders are projected to deliver 6 to 7 percent revenue growth, which gives them an unusual mix of conditions: enough fundamental health to invest, enough macroeconomic uncertainty (tariffs, capital costs, M&A scrutiny) to force discipline about where the investment goes.

That discipline is producing visible budget shifts. PwC's medtech outlook argues that the next 12 to 24 months are a critical window for medtech companies to modernize commercial execution, reshape operating models for speed, and reallocate commercial spend toward high-growth therapeutic categories. The recommendation is direct: high-growth categories merit full sales coverage, digital engagement, and AI-augmented account teams, while mature businesses can be sustained through leaner approaches including AI agents and centralized account support.

Investor pressure reinforces the reallocation logic. The EY CEO Outlook Survey cited in the Pulse report notes that 84 percent of life sciences CEOs expect investors to hold companies accountable for return on capital allocation. For commercial leaders, that translates into board-level visibility on every category of marketing and sales investment.

Where the Money Is Moving

Five reallocation patterns appear consistently across companies running this transition well.

Hybrid Sales Coverage Replacing Rep-Only Models

The largest structural shift is in how companies cover accounts. McKinsey's analysis of the future of medtech sales finds that top-performing companies are augmenting traditional field sales with remote-sales organizations to better match customer preferences and reduce cost to serve. The hybrid model is now the operating norm for high-growth categories.

The supporting data is striking. Veeva Pulse field research, summarized in coverage of HCP engagement benchmarks, shows that sales calls where reps share digital content drive 2.5 times more new patient starts than calls without it. Organizations that get content into roughly 70 percent of meetings outperform laggards (who manage 18 percent) by measurable margins. Device makers running this approach report double-digit territory revenue increases and reduced travel spend as reps move away from low-yield visits.

The reallocation here is not "less rep, more digital." It is rep coverage redesigned around where digital does the work better, freeing the rep for the high-value conversations only an in-person visit can hold.

Digital HCP Engagement Becoming the Default Channel

The shift in HCP engagement patterns is one of the most quantifiable trends in medical device commercial operations. Veeva Pulse data, reported by Fierce Pharma, shows that companies that push inbound digital channels see HCP engagement shift from 78 percent in-person and 22 percent digital to 42 percent in-person and 58 percent digital. In-person volumes are maintained or even grow, but digital becomes the dominant share of total engagement.

For Outcomes Rocket's own perspective on what this looks like inside the program, the medtech digital marketing playbook details how channels like Doximity, Sermo, LinkedIn, and HCP-credentialed programmatic networks combine into a coordinated engagement layer alongside rep activity. The companies doing this well are reallocating budget from broad-reach traditional media into precision HCP digital, where credentialed targeting and clinical-context delivery produce measurable engagement gains.

Therapeutic Category Concentration

Reallocation is increasingly category-specific, not company-wide. EY's Pulse report identifies pulse field ablation, structural heart, robotics, and diabetes as the high-growth categories where leading medtech companies are concentrating disproportionate investment. Orthopedics is also surging, recording 16 percent revenue growth, and ophthalmics is up 28 percent.

The implication for commercial leaders is straightforward. Budget that historically spread evenly across a portfolio is now concentrating in categories where the growth trajectory justifies premium commercial investment, with mature categories sustained on leaner coverage. This is the reallocation logic that produces the outsized top-line growth PwC's analysis describes.

AI-Augmented Commercial Operations

AI is moving from pilot to operating layer in medical device commercial functions. EY's CEO Outlook cited in the Pulse report notes that 84 percent of life sciences CEOs agree the focus needs to be on data quality and integration to optimize the impact of medtech AI, not on adding more tools.

The reallocation pattern follows. Investment is shifting away from disconnected point AI tools toward integrated data infrastructure that makes account research, predictive scoring, content personalization, and rep enablement work as a coordinated system. McKinsey's transformation imperative analysis positions commercial excellence augmented by AI as a no-regrets move, requiring medtech companies to upskill sales forces with digital and AI-enabled capabilities and develop tailored engagement strategies.

The companies running this well are not increasing AI spend in isolation. They are reallocating from legacy commercial operations infrastructure into AI-enabled commercial systems that compound over time.

Account-Based Programs Replacing Broad Demand Generation

Medical device sells into a finite universe of high-value accounts: a few thousand hospitals, a few hundred IDNs, a defined set of academic medical centers. The reallocation toward account-based programs reflects that reality. Broad lead generation produces volume; ABM produces buying-committee progression inside the accounts that actually convert.

Outcomes Rocket research on the state of account-based marketing found that coordinated ABM programs deliver an average ROI of 137 percent, with nearly half of organizations reporting that ABM generates their highest commercial return. In medical device specifically, this is the structural fit between how marketing operates and how buying actually happens.

Where is your medical device program reallocating budget?

Outcomes Rocket helps medical device commercial leaders rebuild their commercial mix for hybrid sales coverage, ABM, and AI-enabled operations.

→ Talk to a Medical Device Marketing Expert

The Categories of Spend That Are Quietly Underperforming

Reallocation is not only about where new investment goes. It is about which categories are being trimmed or restructured because they no longer earn their place. Three patterns appear most consistently across medical device commercial reviews.

Generic Conference Activation

The traditional approach (large booth presence at industry events, broad sponsor packages, undifferentiated brand exposure) is underperforming for many medical device companies. The buying committee a CMO needs to reach is often not attending the same meetings the marketing team has been sponsoring out of habit.

The reallocation pattern is toward category-specific events, KOL-led satellite sessions, and targeted hospitality programs that bring specific buying committee roles into structured conversations. The conference spend gets smaller in total dollars but produces more pipeline because it is aimed at the right people.

Untargeted Programmatic Display

General-population programmatic display reaches medical device buyers inefficiently. The audience is too small relative to the channel's targeting precision. Companies are reallocating from broad programmatic toward HCP-credentialed networks (Doximity, Sermo, Medscape, and specialty-specific programmatic) where verified clinical targeting produces engagement that broader networks cannot.

Mature Category Rep Coverage Without Digital Augmentation

Continuing full rep coverage in mature, low-growth product categories without digital augmentation is one of the most expensive habits in medical device commercial operations. PwC's analysis is direct: mature businesses can be sustained through leaner approaches including AI agents and centralized account support, freeing the field investment for high-growth categories. Companies still running 2015-era field models on mature categories are underperforming the reallocation curve.

What the Strongest Reallocations Have in Common

Across the medical device commercial leaders running these transitions effectively, three patterns repeat.

The reallocation is tied to a clear strategic frame. It is not "we are spending less on conferences." It is "we are reallocating from broad conference activation into category-specific KOL programs that produce VAC engagement." The strategic logic comes first. The budget shift follows.

Measurement infrastructure changes before the budget does. Companies running good reallocations rebuild their attribution and account-level tracking before they shift spend, so they can see what is actually working in the new mix. Companies that shift spend first and try to measure after often cannot tell whether the reallocation produced commercial gain or noise.

The reallocation respects long medical device sales cycles. Quick reallocations based on quarterly pipeline data tend to misread medical device dynamics, where the activity in months one through six determines what happens in months twelve through eighteen. Strong reallocations work against the longer rhythm. For more on this dynamic, the strategies that win long medical device sales cycles piece covers the buyer-journey sequencing in depth.

What This Means for Commercial Leaders Now

The medical device CMOs and commercial VPs running these reallocations well are not asking whether to make the shift. They are asking how fast, in which categories, and against which measurement infrastructure. The companies still debating whether digital, hybrid sales, ABM, and AI-enabled operations belong in their commercial mix are increasingly going to find themselves looking up at competitors who already operationalized the reallocation.

The honest read of the current moment is that the cost of waiting is higher than the cost of moving. The medtech and medical device commercial environment has decisively shifted toward hybrid coverage, precision HCP digital, account-based programs, AI-enabled operations, and category-concentrated investment. The data is consistent across EY, McKinsey, PwC, Veeva, and the industry analysts watching the category. The remaining question is execution.

For commercial leaders evaluating where to start, the Outcomes Rocket medical device marketing program is built around exactly this reallocation logic. The piece on turning portfolio insight into commercial momentum covers the buyer intelligence layer that makes these reallocations defensible to the board.